Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Second Sight Medical Products, Inc. (NASDAQ: EYES).

Full DD Report for EYES

You must become a subscriber to view this report.


Recent News from (NASDAQ: EYES)

Second Sight Medical Products (EYES) CEO Will McGuire on Q3 2018 Results - Earnings Call Transcript
Second Sight Medical Products (EYES) Q3 2018 Earnings Conference Call November 7, 2018 04:30 PM ET Executives Lisa Wilson - IR Will McGuire - President and CEO John Blake - CFO Analysts Amit Dayal - H.C. Wainwright Presentation Operator Ladies and gentlemen, thank...
Source: SeekingAlpha
Date: November, 07 2018 20:47
Second Sight beats by $0.03, misses on revenue
Second Sight (NASDAQ: EYES ): Q3 Non-GAAP EPS of -$0.11 beats by $0.03 ; GAAP EPS of -$0.12 beats by $0.02 . Revenue of $2.2M (+37.5% Y/Y) misses by $0.28M . Press Release More news on: Second Sight Medical Products, Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: November, 07 2018 17:01
Second Sight Reports Third Quarter 2018 Financial Results
Encouraging Interim Results of Orion ® Feasibility Study with Four Subjects Cleared for Home Use LOS ANGELES, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufactur...
Source: GlobeNewswire
Date: November, 07 2018 16:01
Second Sight Announces Final 2019 Medicare Hospital Outpatient Payment Rate for the Argus II Retinal Prosthesis System
LOS ANGELES, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of use...
Source: GlobeNewswire
Date: November, 06 2018 16:01
Second Sight to Discuss Third Quarter 2018 Financial Results on November 7, 2018 Conference Call
Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, will release its 2018 third quarter financial results on Wednesday, November 7, 2...
Source: Business Wire
Date: October, 30 2018 08:00
Second Sight (EYES) Presents At Rodman & Renshaw.C. Wainwright 20th Annual Global Investment Conference - Slideshow
The following slide deck was published by Second Sight Medical Products in conjunction with this Read more ...
Source: SeekingAlpha
Date: September, 06 2018 15:12
Second Sight Appoints Pat Ryan Chief Operating Officer
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, announced today that Pat Ryan has been appointed Ch...
Source: Business Wire
Date: September, 04 2018 08:00
Analysis: Positioning to Benefit within C&J Energy Services, LivePerson, Kadmon, Cara Therapeutics, CorMedix, and Second Sight Medical Products - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of C&J Energy Services, Inc. (NYSE:CJ), LivePerson, Inc. (NASDAQ:LPSN), ...
Source: GlobeNewswire
Date: August, 27 2018 07:40
Second Sight to Present at Investor Conferences in September
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that Will McGuire, President and Ch...
Source: Business Wire
Date: August, 22 2018 08:00
Second Sight Completes $5.0 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors
Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that i...
Source: Business Wire
Date: August, 16 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-111.070.94361.070.921,038,369
2018-12-101.071.05011.120.902,200,942
2018-12-070.96691.081.080.911,573,572
2018-12-060.990.95111.020.9208582,972
2018-12-051.051.0061.090.9301858,690

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-11153,574339,92545.1788Short
2018-12-10367,230683,52853.7257Short
2018-12-07404,397609,44566.3550Short
2018-12-0683,168157,24352.8914Short
2018-12-04173,552304,98856.9045Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EYES.


About Second Sight Medical Products, Inc. (NASDAQ: EYES)

Logo for Second Sight Medical Products, Inc. (NASDAQ: EYES)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $122,745,220 - 05/16/2018
    • Authorized: 200,000,000 - 05/01/2018
    • Issue and Outstanding: 59,875,717 - 05/01/2018

     


    Recent Filings from (NASDAQ: EYES)

    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 15 2018
    Amendment to a SC 13D filing
    Filing Type: SC 13D/AFiling Source: edgar
    Filing Date: May, 14 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 11 2018
    Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
    Filing Type: DFiling Source: edgar
    Filing Date: May, 08 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 08 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 01 2018
    Official notification to shareholders of matters to be brought to a vote (Proxy)
    Filing Type: DEF 14AFiling Source: edgar
    Filing Date: April, 13 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 09 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: March, 27 2018
    Annual report with a comprehensive overview of the company
    Filing Type: 10-KFiling Source: edgar
    Filing Date: March, 20 2018

     

     


    Daily Technical Chart for (NASDAQ: EYES)

    Daily Technical Chart for (NASDAQ: EYES)


    Stay tuned for daily updates and more on (NASDAQ: EYES)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: EYES)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EYES is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of EYES and does not buy, sell, or trade any shares of EYES. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/